ARVN
NASDAQ
$8.02
Arvinas Inc (ARVN)
Arvinas, Inc., a clinical-stage biopharmaceutical company, is dedicated to the discovery, development, and commercialization of therapies to break down disease-causing proteins. The company is headquartered in New Haven, Connecticut.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $14.79 (+84.41%)
Market Cap
$534M
Revenue 5Y CAGR
+33.48%
Free Cash Flow Yield
-48.10%
Beta (5Y)
1.12
Price Chart
Valuation
Market Cap$534M
Forward P/E17.86
P/S5.98
P/B1.38
Profitability
Total Revenue (TTM)$89M
Gross Profit (TTM)$120M
EBITDA-$251M
Profit Margin-247.5%
Operating Margin-405.1%
EPS-$3.29
Financial Health
Debt-to-Equity0.1%
Free Cash Flow Yield-48.10%
Growth & Risk
EPS 5Y CAGR+1.07%
Revenue 5Y CAGR+33.48%
FCF 5Y CAGR+16.87%
Beta (5Y)1.12
Sharpe Ratio0.27